quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:05:00·102d
PRRelease
Atara Biotherapeutics Inc. logo

PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION

ATRA· Atara Biotherapeutics Inc.
Health Care
Original source

Companies

  • ATRA
    Atara Biotherapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 13UpdateCanaccord Genuity$6.00
  • Nov 9UpdateEvercore ISI-
  • Nov 9UpdateH.C. Wainwright-
  • Nov 9UpdateMizuho$1.00
  • Jul 20UpdateCitigroup$3.00
  • Jul 13UpdateJP Morgan$10.00

Related

  • SEC29d
    SEC Form EFFECT filed by Atara Biotherapeutics Inc.
  • SEC29d
    SEC Form 424B3 filed by Atara Biotherapeutics Inc.
  • INSIDER35d
    SEC Form 4 filed by Panacea Innovation Ltd
  • SEC37d
    SEC Form S-3 filed by Atara Biotherapeutics Inc.
  • SEC38d
    SEC Form 424B5 filed by Atara Biotherapeutics Inc.
  • SEC38d
    SEC Form 10-K filed by Atara Biotherapeutics Inc.
  • SEC38d
    Atara Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR38d
    Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022